FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 30, 2026
Genprex, Inc. (GNPX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
Net income
$-16.23M
+23.1% vs prior year
Operating cash flow (TTM)
$-15.56M
-10.5% vs year-ago TTM
Free cash flow
$-17.62M
-23.1% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
9.04M
-62.6% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GNPX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1595248
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Operating income | -$15.5M | -$21.2M | -$31.1M | -$23.8M | -$20.7M |
| Net income | -$16.2M | -$21.1M | -$30.9M | -$23.7M | -$20.7M |
| Operating cash flow | -$15.3M | -$17.9M | -$24.7M | -$17.6M | -$14.3M |
| Free cash flow | — | — | — | -$17.6M | -$14.3M |
| Total assets | $10.2M | $4.1M | $10.7M | $25.1M | $42.9M |
| Total liabilities | $2.2M | — | — | — | — |
| Stockholders' equity | $8.0M | $1.6M | $7.4M | $22.3M | $41.3M |
| Cash and investments | $7.8M | $1.6M | $6.7M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 491 Genprex, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.